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Abstract	  
Blood clots affect over half a million Americans each year and have a high 
mortality rate. Current anticoagulants have been historically successful, but can 
dangerously increase bleeding risk. Using chromogenic substrate assays, I tested almost 
1,000 compounds from the Tidwell library of cationic compounds and analyzed their 
ability to inhibit five specific coagulation proteases that are involved in blood clot 
formation. A small number of promising compounds inhibited only one coagulation 
enzyme. Another member of my lab performed Prothrombin Time (PT) and Activated 
Partial Thromboplastin Time (APTT) assays for each of these compounds. Further 
analysis showed that the compounds that were deemed successful in the PT and APTT 
had very little overlap with those that successfully inhibited only one coagulation 
enzyme. These results suggest that current clinical assay methods may not be ideal 
indicators of thrombotic state. These studies provide useful insight into how to assess 
successful anticoagulants and will ideally result in a new therapeutic antithrombotic. 
  





Venous thromboembolisms (VTE), specifically deep vein thromboses (DVT) and 
pulmonary embolisms (PE), pose a significant health risk in America. According to the 
American Heart Association, over 250,000 Americans are hospitalized annually due to 
thrombotic events and some studies estimate up to 600,000 Americans suffer a VTE each 
year [1, 2]. A thrombosis occurs when the coagulation system is inappropriately activated 
inside a blood vessel, forming a blood clot that obstructs blood flow. Thrombotic events 
have high morbidity and mortality rates. About twenty percent of DVTs and pulmonary 
embolisms are immediately fatal and approximately thirty percent of people diagnosed 
will die within thirty days [1].  
Even though there is such a high rate of incidence and death, there are very few 
anticoagulant drugs currently available to treat vascular thrombosis. The two most 
common anticoagulant drugs, heparin and warfarin, have significant drawbacks. Heparin 
has been used clinically for over 70 years and is still considered a high-risk 
pharmaceutical [3]. It is useful due to its immediate effects, but it requires parenteral 
administration and can cause osteoporosis with long-term use [4].  Warfarin can be 
administered orally and is given long-term in low doses to reduce clotting risk. 
Unfortunately, warfarin has a narrow therapeutic window and overdosing can lead to 
dangerous hemorrhage. Fatal bleeds are seen in 1% to 3% of patients [5]. Still, heparin 
and warfarin are often prescribed together in a dual system to break up a clot and reduce 
immediate clot risk. Recently, the FDA has approved several new, direct-acting 
anticoagulants, but the field of pharmaceuticals is still far too limited to meet the current 
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need in the population. Developing small, targeted molecules that can interact with 
coagulation proteases could offer better specificity and selectivity than seen in warfarin 
or heparin and reduce negative side effects. Below is a schematic showing the intricacies 
of coagulation, which adds to the difficulty of creating new anticoagulants (Figure 1.)   
 
Figure 1. The details of coagulation, showing the intrinsic, extrinsic, and common 
pathways. 
In 1964, the process of coagulation was first described as a “cascade of 
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Figure 2. Division of coagulation into the cascade model. Each Roman numeral 
represents a serine protease or cofactor that is activated during coagulation and in turn 
activates the following protease until fibrin is produced.  
 
Two of the most common clinical assays used to assess thrombotic state are 
Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT). PT measures 
the amount of time it takes for the “extrinsic” pathway to be activated and produce fibrin. 
aPTT measures the time for “intrinsic” pathway activation. Unfractionated heparin 
extends aPTT, but each laboratory must determine the therapeutic time range based on 
their own aPTT system [7]. Warfarin extends Prothrombin Time. Some new 
anticoagulants, specifically rivaroxaban and dabigatran, do not require routine 
coagulation monitoring like heparin and warfarin do [8, 9]. But, there are still clinical 
settings where being able to quantify blood levels of rivaroxaban and dabigatran is useful 
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or necessary. aPTT gives an approximation of dabigatran activity, but is not linear over 
clinically used concentrations. Instead, diluted thrombin time (dTT) is a more sensitive 
assay to the effects dabigatran [10].  In short, most major anticoagulants are sensitive to 
different assays, which make assessing thrombotic state difficult in a clinical setting. 
This research was conducted as part of an American Heart Association grant 
originally designed to identify and evaluate novel, small molecules as therapeutic 
anticoagulants to decrease harm and death due to thrombotic events. The grant focused 
on analyzing the Tidwell Library of compounds, synthesized by Dr. Richard Tidwell, a 
medicinal chemist in the Department of Pathology and Laboratory Medicine. Previously, 
the compounds were screened as anti-viral agents and anti-protozoan agents, among other 
things. Approximately 1500 compounds were made available to our lab to be screened as 
anticoagulant agents. We developed a tiered system to assess antithrombotic properties, 
choosing the most successful compounds from each phase to the next (Figure 3).  
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Figure 3. Our tiered plan to analyze the Tidwell library of cationic compounds. 
While we are moving into Phase 2 and still analyzing the Tidwell compounds, our current 
data has provided insight into our methods and the current clinical assays used to assess 
thrombotic state.  
 
 
Materials and Methods 
 
Tidwell Library 
The Tidwell lab generously provided us with 5 mg samples of their library of 
cationic compounds; approximately 50 compounds were received weekly for the duration 
of the project. To date we have received 1400 compounds. Each compound was taken up 
in 500 µL of DMSO for a desired concentration of 10 mg/mL. If the compound dissolved 
completely, two aliquots of 100 µL each were made. The compounds were labeled and 
stored in the -80°C freezer. 
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Compounds that did not dissolve completely 500 µL of DMSO were incubated at 
37°C for 15 minutes. If still insoluble, the compounds were incubated at 60°C for 15 
minutes. If incubation at 60°C was ineffective, an additional 500 µL of DMSO was added 
to lower the concentration to 5 mg/mL. Incubation was repeated if necessary. If still not 
dissolved, 1000 µL of DMSO were added to lower the concentration to 2.5 mg/mL and 
the compound was incubated as necessary. If still insoluble, the compound was declared 
insoluble for our purposes and stored. To date, there are 138 insoluble compounds. 
 
Prothrombin Time (PT) 
 Prothrombin Time assays were run by Jasmine Dennis.  
The Neoplastine-Cl Plus reagent was pre-warmed at 37oC for 30 minutes. Plasma 
(VisuCon-F pooled plasma, Affinity Biologicals) and Tidwell compounds were warmed 
in a 37oC dry bath for 10-15 minutes until thawed. Cuvette strips with one magnetic steel 
ball in each (Diagnostica Stago) were warmed for 3 minutes. Tidwell compounds were 
diluted in plasma to 100 µg/mL. Controls of plasma and plasma with 1% DMSO were 
made. This assay was run in duplicate on a Diagnostica Stago STart 4 Hemostasis 
Analyzer, which measured the amount of time it took for the plasma to clot after the 
reagent was added. 
Each cuvette strip (containing 50 µL of plasma-diluted inhibitor) was placed in an 
incubation well for 60 seconds. After that, the cuvette was moved to the recording well. 
Simultaneously, 100 µL of Neoplastine-Cl Plus reagent was added and recording began. 
For values that exceeded 20 seconds, compounds were diluted 1:2 with plasma and tested 
again.  
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Activated Partial Thromboplastin Time (APTT) 
Activated Partial Thromboplastin Time assays were run by Jasmine Dennis. 
This assay was run in duplicate on a Diagnostica Stago STart 4 Hemostasis 
Analyzer, which measured the amount of time it took for the plasma to clot. The PTT-A 
reagent was pre-warmed at 25oC and CaCl2 (25 mM, pH 7.4) at 37oC for 20 minutes. 
Plasma (VisuCon-F pooled plasma) and Tidwell compounds were warmed in a 37oC dry 
bath for 10-15 minutes until thawed. Cuvette strips with one magnetic steel ball in each 
(Diagnostica Stago) were warmed for 3 minutes. Tidwell compounds were diluted in 
plasma to 100 µg/mL. Controls of plasma and plasma with 1% DMSO were made. 
Each cuvette strip (containing 50 µL of plasma-diluted inhibitor and 50 µL of 
PTT-A reagent) was placed in an incubation well for 180 seconds. Then, the cuvette was 
moved to the recording well where 50 µL of CaCl2 was added and recording began 
simultaneously. For compounds that exceeded 120 seconds, compounds were diluted 1:2 
with plasma and the assay was repeated until the value was below 50 seconds. 
 
Chromogenic Substrate Assay 
 The assay was performed in 96-well U-bottomed assay plates. The buffer used 
was HEPES 20 mM, NaCl 150 mM, polyethylene glycol 0.1%, and CaCl2 5 mM pH 7.4. 
The buffer base was prepared in advance and calcium was added daily to the needed 
amount. Purified, activated coagulation enzymes (thrombin, FIXa, FXIa, FXa, and FVIIa) 
were stored at their stock solutions in glycerol in the -20°C freezer to protect from 
degradation. They were added to buffer at appropriate individual concentrations. Due to 
the varying activity levels, different concentrations of each protease were used (Appendix 
1). Two corresponding chromogenic substrates, Pefachrome FIXa and Pefachrome VIIa, 
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were used (Appendix 2). All substrates had a final concentration of 200 µM. The Tidwell 
inhibitors were added to the buffer at a final concentration of 25 µg/mL.  
The substrate’s cleavage (reflecting enzyme activity and therefore inhibitor 
strength) was measured by reading the absorbance at 405 nm for 20 minutes using a 
ThermoMax Microplate Reader (Molecular Devices). Inhibitor potency was expressed as 
a percentage by comparing each inhibitor well to a control well. 
 
 
Results and Discussion 
 
PT and APTT  
 In total, 1213 Tidwell compounds were assayed using PT and aPTT. The 
compounds were categorized according assay times (Table 1). These times were chosen 
to reflect standard, elevated, and dangerously prolonged values of PT and aPTT. The 
majority of the compounds did not prolong PT or aPTT significantly.  
 PT < 16 sec PT 16 – 32 sec PT > 32 sec 
aPTT < 50 sec 703 37 1 
aPTT 50 – 119 sec 105 198 6 
aPTT ≥ 120 sec 16 76 71 
Table 1. Tidwell Compound results based on PT and APTT data. 71 compounds had very 
prolonged PT and aPTT times. The majority of the compounds (703) did not prolong 




Chromogenic Substrate Assays 
 Originally, our lab was going to use PT and aPTT data to choose a select number 
of compounds to further analyze using chromogenic substrate assays. Because our PT 
and aPTT results fell in the non-prolonged range for both assays, we decided to analyze 
all of the compounds with chromogenic substrate assays. In total, 798 compounds have 
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been analyzed using Chromogenic Substrate Assays. A compound was labeled an 
inhibitor if it decreased enzyme activity by 70% compared to control. Based on those 
criteria, 566 compounds showed no significant inhibition of any coagulation protease. 
We did find 90 compounds that inhibited three or more coagulation proteases and dubbed 
them “pan-inhibitors”. All of these compounds inhibited thrombin, FXa, and at least one 
other enzyme. Sixty-six compounds were dual enzyme inhibitors. As shown in Table 2, 
all but three of the dual-enzyme inhibitors inhibit thrombin or factor Xa. We are unsure 
of an explanation for this trend involving thrombin and FXa, but it may be a future area 
of inquiry. 
 FIXa FXIa FXa FVIIa 
Thrombin 2 7 39 2 
FIXa  0 2 3 
FXIa   10 0 
FXa    1 
Table 2. Numbers of dual-enzyme inhibitors. It is interesting to note that there are 66 
dual-enzyme inhibitors. All but three inhibited either thrombin or FXa.  
 
 The chromogenic substrate assays identified 76 single-enzyme inhibitors (Table 
3) .The majority of these inhibitors were thrombin inhibitors. These inhibitors are of 
particular interest to our lab due to their targeted nature, especially FXIa. Factor XI 
deficiency causes Hemophilia C, a form of hemophilia that has a lower and milder 
bleeding tendency than Hemophilia A or B [11]. Inhibition of FXIa may reduce 
thrombotic tendency without dangerously increasing bleeding risk. 
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Thrombin FIXa FXIa FXa FVIIa 
39 8 10 19 8 
Table 3. Numbers of single-enzyme inhibitors. These inhibitors are of particular interest 
to our lab. Other studies have shown that single enzyme inhibitors can reduce thrombotic 
risk without increasing bleeding tendency. 
  
Comparison of PT/aPTT results and Chromogenic Substrate Assays  
 We have analyzed fewer compounds using chromogenic substrate assays than 
PT/aPTT, but the sample size is large enough that we expect the current data will reflect 
the overall trends of the Tidwell compounds. Figure 4 compares the PT and aPTT data 
with that from the chromogenic substrate assays.  
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Figure 4. A graphic representation of PT and aPTT data combined with chromogenic 
substrate assay data. The blue circles represent single enzyme inhibitors, scaled by size. 
The numbers to the left of the circle note how many single enzyme inhibitors fall in each 
PT/aPTT time category. The purple circles represent multi-enzyme inhibitors (3 or more 
proteases inhibited). The number to the right of the circle notes how many are in each 
category.  
 
We expected the compounds that fell in the highly prolonged range (PT > 32 sec, aPTT ≥ 
120 sec) to be very potent single enzyme inhibitors. Instead, our data show the 71 
compounds in that range are primarily multi-enzyme inhibitors. Most of the single 
enzyme inhibitors, regardless of potency, fell in the non-prolonged range (PT >16 
seconds, aPTT > 50 seconds) or the slightly prolonged range (PT 16-32 seconds, aPTT 
50-119 seconds). Only one single enzyme inhibitor fell in the very prolonged range. 
According to our observations, prolongation of PT and aPTT depends on breadth of 
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inhibition of coagulation proteases. In a previous study done in this lab by Chantelle 
Rein-Smith, multi-enzyme inhibitors were successful anticoagulants, but also 
dramatically and fatally decrease blood pressure in mouse injury models. Therefore, 
prolonged PT and aPTT are not good indications of anticoagulant potential based on our 
standards. 
 
Analysis of Current Anticoagulants 
As acknowledged before, there are serious drawbacks to historic anticoagulants, 
namely heparin and warfarin. There has been a shift in anticoagulant research to very 
targeted compounds that inhibit specific serine proteases or cofactors; targeted 
compounds have had success in reducing thrombotic risk without increasing bleeding 
tendency. Unfortunately, many of these compounds currently on the market cannot be 
assayed using PT or aPTT. 
Dabigatran etexilate mesylate (marketed as Pradaxa) is a relatively new, oral, 
direct thrombin inhibitor. Compared to warfarin, it has a lower risk of clot-related 
strokes, brain bleeds, and death [12]. And, unlike warfarin, dabigatran does not require 
frequent monitoring [13]. Dabigatran has very little effect on PT at clinical 
concentrations. aPTT is only suitable to provide a qualitative analysis of dabigatran in 
patient plasma; the aPTT curve flattens out at high clinical concentrations, so aPTT is not 
appropriate to assess the quantitative effect of dabigatran [14]. 
A study of another targeted anticoagulant, apixaban, showed that only one PT 
reagent was sensitive enough to detect apixaban levels across clinical concentrations. 
None of the seven aPTT reagents were sensitive enough to analyze apixaban levels [15].  
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It should be noted that not all new, targeted anticoagulants fail to prolong PT or 
aPTT assays. For example, rivaroxaban is a targeted factor Xa inhibitor and prolongs PT 
and aPTT [16].  
Our results agree with current research that shows PT and aPTT are not enough to 
assess thrombotic state in patients using novel targeted anticoagulants. These common 
clinical assays are not obsolete, but they can no longer fully evaluate patient status with 





 Our lab is continuing with analysis of Tidwell compounds to identify future 
anticoagulants. Many compounds have shown potential in the initial assays. Our next step 
is to analyze the effects of the inhibitors on overall thrombin generation using a 
Calibrated Automated Thrombogram (CAT) assay. With the most successful compounds 
from our in vitro experiments, we hope to move into mouse models. Our strategy is to use 
a mouse model of a saphenous vein ferric chloride injury to test the in vivo anticoagulant 
properties of our compounds. 
Overall, the initial assays were very telling about the way we approach 
identification of anticoagulants. It has previously been shown that currently marketed 
novel targeted anticoagulants can have altered results in clotting assays, including PT and 
aPTT [17]. Our data are consistent with these observations and provide one explanation 
as to why this may occur. Individual factor inhibition demonstrated prolongation of 
neither PT nor aPTT. The use of these assays is better suited for analysis of multifactor 
inhibition rather than determination of individual factor inhibition. Chromogenic 
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substrate assays were much more useful to identify successful targeted compounds, but 
currently these assays are not common in clinical settings. Based on our data, 
development of new clinical assay methods should accompany the development of 
targeted antithrombotic compounds. 
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Enzyme Stock concentration Final concentration 
Thrombin 2 µM 4 nM 
Factor IXa 40 µM 200 nM 
Factor XIa 1 µM 2 nM 
Factor Xa 2.5 µM 5 nM 
Factor VIIa 40 µM 100 nM 
Appendix 1. Enzyme concentrations of the chromogenic substrate assay. 
 
 
Enzyme Final Concentration Substrate Final Substrate 
Concentration 
Thrombin 4 nM Pefachrome FIXa 200 µM 
Factor IXa 200 nm Pefachrome FIXa 200 µM 
Factor XIa 2 nM Pefachrome FIXa 200 µM 
Factor Xa 5 nM Pefachrome FVIIa 200 µM 
Factor VIIa 100 nM Pefachrome FVIIa 200 µM 
Appendix 2. Substrate concentrations of the chromogenic substrate assay. 
 
 
